Literature DB >> 31679215

Recent Advances in Cancer Stem Cell Targeted Therapy.

Hakan Akbulut1, Cansu Babahan2, Samira Abdi Abgarmi2, Muge Ocal2, Merve Besler2.   

Abstract

The cancer stem cells (CSCs) are a subpopulation of cancer cells with unique properties of self-renewal and differentiation potential. Recent evidence suggests that these cells might be responsible for tumor relapse and treatment resistance. Conventional cancer treatment modalities like chemotherapy and radiotherapy usually fail in eradicating CSCs in a tumor mass. Preclinical studies aiming at targeting CSCs have yielded great promise to increase the cancer cure rate. Likewise, targeting of conventional chemotherapeutic drugs to the CSCs and new small molecule inhibitors of stem-cell signaling pathways in humans carry the potential of improving the cancer management. Dendritic cell (DC)-based vaccines seem to be safe and efficient tools in targeting CSCs. The combination of DC vaccines with immune-checkpoint inhibitors is also promising. The viral vectors, particularly the oncolytic viruses, targeting CSCs have emerged as potential curative agents in cancer treatment. Here, we review the recent advances in targeting CSCs via stem cell markers, signaling pathways, immune system, cancer vaccines, and viral treatments.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31679215     DOI: 10.1615/CritRevOncog.2018029574

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  3 in total

Review 1.  The Protective Role of 4-Acetylarylquinolinol B in Different Pathological Processes.

Authors:  Huijie Zhao; Huiyang Liu; Yihan Yang; Honggang Wang
Journal:  Curr Issues Mol Biol       Date:  2022-05-23       Impact factor: 2.976

Review 2.  Correlation between amino acid metabolism and self-renewal of cancer stem cells: Perspectives in cancer therapy.

Authors:  Qi Zhang; Wei Li
Journal:  World J Stem Cells       Date:  2022-04-26       Impact factor: 5.247

3.  A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients.

Authors:  Shengkai Geng; Yipeng Fu; Shaomei Fu; Kejin Wu
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.